Zenflow, Inc. has announced the close of an oversubscribed US$52 million Series D financing round and a new exclusive U.S. distribution agreement with Cook Medical. The developments will support the commercialization of the Zenflow Spring System, a minimally invasive treatment for benign prostatic hyperplasia, also known as BPH. The company secured U.S. Food and Drug Administration premarket approval for the device in December 2025.
Series D Financing and Investor Support
The Series D round was led by Cook Medical, with participation from new investor ClavystBio and existing investors Invus Opportunities, F-Prime, Medtech Venture Partners, and others. Venture debt financing from HSBC Bank USA, N.A. and Trinity Capital provided additional support. Zenflow stated that the proceeds will accelerate its commercial launch following the December 2025 FDA approval.
Exclusive U.S. Distribution Agreement
Under the exclusive U.S. distribution agreement, Cook Medical will distribute the Zenflow Spring System to urologists and health systems nationwide. The partnership combines Zenflow's clinical and operational expertise with Cook Medical's established commercial presence in urology. Zenflow expects the alliance to expand patient access to the novel BPH therapy across the country.
Clinical Significance of the Zenflow Spring System
The Zenflow Spring System is described as the first and only product to offer simple, in-office treatment for BPH with multiple sizing options and full reversibility if desired. It introduces a new category known as first-line interventional therapy, giving physicians a device-based alternative to drug therapy. Zenflow highlights long-term durability, no post-procedure catheter, and preservation of sexual function among its key advantages.
Understanding Benign Prostatic Hyperplasia
Benign prostatic hyperplasia, or an enlarged prostate, occurs when the prostate grows and presses on the urethra, making urination more difficult. Symptoms can include a weak or interrupted stream, increased frequency and urgency, nighttime urination, and incomplete bladder emptying. Zenflow estimates that 32 million men over age 60 in the United States and 79 million men worldwide live with the condition.
Leadership Perspectives
Andrew Cleeland, Chairman of the Board of Directors of Zenflow, said that combining Cook Medical's commercial expertise with Zenflow's operational strength will meaningfully accelerate the launch of Spring treatment. Shreya Mehta, Chief Executive Officer of Zenflow, described Cook Medical's deep urology relationships and proven commercialization capabilities as an ideal fit for bringing the technology to patients. DJ Sirota, Senior Vice President of Cook's MedSurg Division, said the system provides meaningful advancement in BPH care through its first-line option and reversibility.
Commercial Launch Plans
Zenflow plans to use the new capital to build its commercial infrastructure and support the initial launch of the Zenflow Spring System following FDA premarket approval. The company is focused on establishing the Spring System as a first-line interventional therapy option for urologists treating men with BPH. The Cook Medical distribution agreement is expected to accelerate market adoption through an established sales and support network in urology.
Company Overview
Zenflow is a medical device company focused on developing innovative therapies for benign prostatic hyperplasia. Its flagship Zenflow Spring System is designed to provide durable symptom relief with a minimally invasive approach that preserves future treatment options. The company states that the system also supports physician workflow efficiency for urology practices.
The oversubscribed Series D round and the Cook Medical distribution agreement mark a significant commercial milestone for Zenflow following its recent FDA approval. With a large patient population and a differentiated, reversible device-based option, the company is positioned to scale its presence in urology. The new funding and partnership are expected to broaden access to the Zenflow Spring System and strengthen its role in the BPH treatment landscape.